



**M Flepp**

**Contact**

M Flepp

## Publications (16)

Hampel B, Nguyen H, Delaloye J, Rougemont M, Bernasconi E, Rauch A, Günthard H, Braun D, Fehr J, Schmidt A, Nicca D, Kusejko K, Kouyos R, Böni J, Flepp M, Stöckle M, Conen A, Béguelin C, Künzler-Heule P, Swiss HIV Cohort Study Group. Chemsex drugs on the rise: a longitudinal analysis of the Swiss HIV Cohort Study from 2007 to 2017. *HIV Med* 2019

Weber R, the Swiss HIV Cohort Study (SHCS), Schultze D, Schöni-Affolter F, Schüpbach J, Speck R, Taffé P, Tarr P, Telenti A, Trkola A, Vernazza P, Ledergerber B, Kowalska J, Ruppik M, Rickenbach M, Spoerri A, Furrer H, Battegay M, Cavassini M, Calmy A, Bernasconi E, Schmid P, Flepp M, Yerly S. Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. *HIV Med* 2012

Magenta L, Bernasconi E, Bucher H, Decosterd L, Cavassini M, Evison J, Vernazza P, Hirschel B, Flepp M, Hasse B, Young J, Richter W, Dell-Kuster S, the Swiss HIV Cohort Study (SHCS). Lipid and Lipoprotein Profile in HIV-Infected Patients Treated with Lopinavir/Ritonavir as a Component of the First Combination Antiretroviral Therapy. *AIDS Res Hum Retroviruses* 2010

Bertschy S, Furrer H, Christen A, Chave J, Flepp M, Schmid P, Schiffer V, Bernasconi E, Cavassini M, Opravil M, Swiss HIV Cohort Study. Discontinuation of maintenance therapy against toxoplasma encephalitis in AIDS patients with sustained response to anti-retroviral therapy. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases* 2006; 12:666-71.

Yerly S, Perrin L, Hirschel B, Rickenbach M, Bru J, Veuthey A, Battegay M, Telenti A, Flepp M, Vernazza P, Chave J, Rizzardì P, Vora S, Swiss HIV Cohort Study. Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. *AIDS (London, England)* 2001; 15:2287-92.

Boubaker K, Francioli P, Rickenbach M, Opravil M, Egger M, Bernasconi E, Chave J, Boggian K, Hirschel B, Haensel A, Furrer H, Sudre P, Flepp M, Telenti A. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. *Clin Infect Dis* 2001; 33:1931-7.

Fellay J, Telenti A, Flepp M, Greub G, Francioli P, Vernazza P, Hirschel B, Battegay M, Furrer H, Bernasconi E, Ledergerber B, Boubaker K, Swiss HIV Cohort Study. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. *Lancet* 2001; 358:1322-7.

Rossi M, Furrer H, Rickenbach M, Weber R, Bernasconi E, Vernazza P, Bucher H, Egloff N, Schiffer V, Telenti A, Flepp M, Swiss HIV Cohort Study. Disseminated *M. avium* complex infection in the Swiss HIV Cohort Study: declining incidence, improved prognosis and discontinuation of maintenance therapy. *Swiss medical weekly : official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology* 2001; 131:471-7.

Furrer H, Egger M, Flepp M, Rickenbach M, Boggian K, Schiffer V, Bucher H, Telenti A, Bernasconi E, Rossi M, Opravil M, Swiss HIV Cohort Study. Discontinuation of primary prophylaxis in HIV-infected patients at high risk of *Pneumocystis carinii* pneumonia: prospective multicentre study. *AIDS* 2001; 15:501-7.

Battegay M, Hirschel B, Bedoucha V, Morgenthaler S, Jaccard C, Malinverni R, Erb P, Sendi P, Flepp M, Bernasconi E, Vernazza P, Swiss HIV Cohort Study. Combined therapy with saquinavir, ritonavir and stavudine in moderately to severely immunosuppressed HIV-infected protease inhibitor-naïve patients. *HIV medicine* 2001; 2:35-42.

Greub G, Flepp M, Francioli P, Janin P, Hirschel B, Piffaretti J, Boggian K, Erb P, Bürgisser P, Furrer H, Perrin L, Grob P, Battegay M, Ledergerber B, Telenti A. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. *Lancet* 2000; 356:1800-5.

Bürgisser P, Vernazza P, Flepp M, Böni J, Tomasik Z, Hummel U, Pantaleo G, Schüpbach J. Performance of five different assays for the quantification of viral load in persons infected with various subtypes of HIV-1. Swiss HIV Cohort Study. *Journal of acquired immune deficiency syndromes (1999)* 2000; 23:138-44.

Weber R, Meyenberger C, Opravil M, Kaiser L, Briner J, Spycher M, Pfyffer G, Altwegg M, Zbinden R, Ledergerber B, Flepp M. Enteric infections and diarrhea in human immunodeficiency virus-infected persons: prospective community-based cohort study. Swiss HIV Cohort Study. *Archives of internal medicine* 1999; 159:1473-80.

Bassetti S, Bernasconi E, Vernazza P, Telenti A, Kaiser L, Flepp M, Rickenbach M, Furrer H, Battegay M, Sudre P. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. *Journal of acquired immune deficiency syndromes (1999)* 1999; 21:114-9.

Furrer H, Flepp M, Rickenbach M, Vernazza P, Telenti A, Battegay M, Hirschel B, Bernasconi E, Opravil M, Egger M, Malinverni R. Discontinuation of primary prophylaxis against *Pneumocystis carinii* pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. *The New England journal of medicine* 1999; 340:1301-6.

Ledergerber B, Francioli P, Furrer H, Flepp M, Sudre P, Vernazza P, Battegay M, Hirschel B, Telenti A, Opravil M, Egger M, Weber R. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. *Lancet* 1999; 353:863-8.

## Projects (0)

No results found.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)